Loading your health companion...
losartan | 2026-03-15 | Source: FDA
NDEA impurity above acceptable limit
Recommended Action:
Stop taking immediately, consult doctor for alternative
metformin | 2026-03-10 | Source: FDA | Lot: LOT-2026-0312
NDMA levels exceed acceptable daily intake
Recommended Action:
Contact pharmacist for non-extended-release alternative
ranitidine | 2026-02-28 | Source: EMA
NDMA contamination risk increases with storage
Recommended Action:
Dispose of all remaining tablets, switch to famotidine
valsartan | 2026-02-20 | Source: FDA
Potential NDEA carcinogen detected in batch
Recommended Action:
Return to pharmacy, request replacement from different manufacturer
acetaminophen | 2026-02-15 | Source: TITCK | Lot: LOT-PR-2026
Dosing instructions missing from packaging
Recommended Action:
Check lot number, contact manufacturer for correct dosing label
omeprazole | 2026-02-01 | Source: TITCK
Cross-contamination with another active ingredient
Recommended Action:
Stop use and return to pharmacy immediately
ibuprofen | 2026-01-25 | Source: TITCK
Tablet hardness below specification - may dissolve too fast
Recommended Action:
No health risk, but exchange at pharmacy if concerned
atorvastatin | 2026-01-18 | Source: FDA
Mislabeled dosage strength on bottle
Recommended Action:
Verify tablet markings match prescribed dose
amoxicillin | 2026-01-10 | Source: EMA
Reduced potency detected before expiration date
Recommended Action:
Get new prescription filled, report to pharmacist
amlodipine | 2026-01-05 | Source: FDA | Lot: AML-2025-1198
Foreign particle found in select batches
Recommended Action:
Check lot number, return affected batch to pharmacy
levothyroxine | 2025-12-28 | Source: FDA
Sub-potent tablets detected in quality testing
Recommended Action:
Get thyroid levels checked, switch to verified batch
pantoprazole | 2025-12-15 | Source: TITCK
Discoloration observed in tablets
Recommended Action:
Visual inspection - discolored tablets should not be taken